Seqens Seqens

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Moberg Pharma","sponsor":"Nice & Green S.A","pharmaFlowCategory":"D","amount":"$21.2 million","upfrontCash":"Undisclosed","newsHeadline":"Moberg Pharma Enters Financing Agreement of Up To SEK 216 Million for Further Investments in MOB-015","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"March 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Moberg Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moberg Pharma Meets Primary Endpoint in the European Phase 3 Study","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"June 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Moberg Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moberg Pharma Intends to Submit a Registration Application in Europe in 2021","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"October 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Moberg Pharma","sponsor":"Undisclosed","pharmaFlowCategory":"D","amount":"$17.5 million","upfrontCash":"Undisclosed","newsHeadline":"Moberg Pharma Decides on fully Guaranteed Rights Issue of Approximately SEK 150 Million","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"November 2020","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Moberg Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moberg Pharma Receives Approval from The EMA's Paediatric Committee","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"September 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Moberg Pharma","sponsor":"Allderma","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Moberg Pharma Enters Into Collaboration with Allderma for Launch in Scandinavia","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"November 2021","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Moberg Pharma","sponsor":"Padagis","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Moberg Pharma and Padagis Sign Agreement For MOB-015 in Israel","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"August 2022","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Moberg Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Moberg Pharma has Completed Enrollment to the Phase 3 Study for MOB-015 in North America","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Phase III","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"October 2023","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III"},{"orgOrder":0,"company":"Moberg Pharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"MOB-015 is Launched in Sweden under the Brand Name Terclara- pharmacies Report Major Demand for the New Medication","therapeuticArea":"Infections and Infectious Diseases","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Small molecule","productStatus":"Approved","date":"February 2024","url1":"","url2":"","graph1":"Infections and Infectious Diseases","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals by Moberg Pharma

    Menu

    Moberg Pharma

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Moberg Pharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              MOB-015 is Launched in Sweden under the Brand Name Terclara- pharmacies Report Major Demand for the New Medication

              Details:

              Terclara (terbinafine) is a topical squalene monooxygenase inhibitor antifungal drug candidate, which is launched in Sweden for the treatment of onychomycosis.

              Lead Product(s): Terbinafine

              Therapeutic Area: Infections and Infectious Diseases Product Name: Terclara

              Highest Development Status: Approved Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable February 07, 2024

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Moberg Pharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Moberg Pharma has Completed Enrollment to the Phase 3 Study for MOB-015 in North America

              Details:

              MOB-015 (terbinafine) is an in-house developed topical formulation, which is investigated for the treatment of onychomycosis and Topline results are expected in January 2025.

              Lead Product(s): Terbinafine Hydrochloride

              Therapeutic Area: Infections and Infectious Diseases Product Name: MOB-015

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 06, 2023

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Moberg Pharma

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Moberg Pharma and Padagis Sign Agreement For MOB-015 in Israel

              Details:

              Under the agreement Padagis is granted exclusive rights to market and sell MOB-015 (terbinafine hydrochloride) in Israel and the Palestinian territories. Moberg Pharma assumes production and supply responsibility.

              Lead Product(s): Terbinafine Hydrochloride

              Therapeutic Area: Infections and Infectious Diseases Product Name: MOB-015

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Padagis

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Agreement August 04, 2022

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Moberg Pharma

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Moberg Pharma Enters Into Collaboration with Allderma for Launch in Scandinavia

              Details:

              The agreement with Allderma complements the existing licensing agreement for MOB-015 in Europe. Allderma is responsible for marketing, distribution and sales in Sweden, Denmark and Norway, while Moberg Pharma is responsible for the manufacture and delivery of the product.

              Lead Product(s): Terbinafine

              Therapeutic Area: Infections and Infectious Diseases Product Name: MOB-015

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Allderma

              Deal Size: Undisclosed Upfront Cash: Undisclosed

              Deal Type: Collaboration November 08, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Moberg Pharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Moberg Pharma Receives Approval from The EMA's Paediatric Committee

              Details:

              MOB-015 is our next-generation nail fungus treatment targeting both over-the-counter (OTC) and prescription markets around the world. The company's timeline remains, with planned submission for MOB-015 in Europe this year and expected market approval in 2023.

              Lead Product(s): Terbinafine

              Therapeutic Area: Infections and Infectious Diseases Product Name: MOB-015

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 22, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Moberg Pharma

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Moberg Pharma Decides on fully Guaranteed Rights Issue of Approximately SEK 150 Million

              Details:

              The proceeds will be used for registration activities and clinical work for MOB-015. When the Rights Issue is completed, the Company intends to terminate the current Convertible Loan Agreement.

              Lead Product(s): Terbinafine

              Therapeutic Area: Infections and Infectious Diseases Product Name: MOB-015

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Undisclosed

              Deal Size: $17.5 million Upfront Cash: Undisclosed

              Deal Type: Financing November 06, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Moberg Pharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Moberg Pharma Intends to Submit a Registration Application in Europe in 2021

              Details:

              MOB-015's superior mycological cure (percentage of patients who were fungus free) has now been demonstrated in two pivotal studies, providing further support for the company's target to make MOB-015 the future market leader in onychomycosis.

              Lead Product(s): Terbinafine

              Therapeutic Area: Infections and Infectious Diseases Product Name: MOB-015

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable October 14, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Moberg Pharma

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Moberg Pharma Meets Primary Endpoint in the European Phase 3 Study

              Details:

              MOB-015 (topical terbinafine) met the primary endpoint in the European Phase 3 study including 452 onychomycosis patients, showing non-inferiority versus topical ciclopirox. Mycological cure was achieved in 84 percent of patients.

              Lead Product(s): Terbinafine

              Therapeutic Area: Infections and Infectious Diseases Product Name: MOB-015

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable June 25, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Moberg Pharma

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Moberg Pharma Enters Financing Agreement of Up To SEK 216 Million for Further Investments in MOB-015

              Details:

              The agreement with N&G enables Moberg Pharma to pursue this potential and conduct an additional clinical study, depending on the outcome of the EU study expected at the end of Q2 2020.

              Lead Product(s): Terbinafine

              Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

              Highest Development Status: Phase III Product Type: Small molecule

              Partner/Sponsor/Collaborator: Nice & Green S.A

              Deal Size: $21.2 million Upfront Cash: Undisclosed

              Deal Type: Financing March 23, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Minakem offers CDMO services for API & HPAPI, generics, regulatory expertise, track record performance & FDA & GMP certifications.
              ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.
              Post Enquiry
              POST ENQUIRY